InvestorSoup.com announces investment report featuring Oncothyreon

InvestorSoup.comMar 24 2010

InvestorSoup.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.investorsoup.com/lp/ONTY

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

Oncothyreon Inc. (ONTY) is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The Company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. ONTY's lead product candidate is Stimuvax, which is a cancer vaccine in phase III development for non-small cell lung cancer (NSCLC).

Message Board Search for ONTY: http://www.boardcentral.com/boards/ONTY

In the report, the analyst notes:

"ONTY reported a loss from operations of $2.8 million for the three months ended September 30, 2009, compared with a loss from operations of $3.6 million for the comparable period in 2008. ONTY also reported a loss from operations of $9.0 million for the nine months ended September 30, 2009, compared with a loss from operations of $13.7 million for the comparable period in 2008. For both the three-month and nine-month periods, the decrease in loss from operations was primarily the result of decreased research and development, manufacturing and general and administrative expenses, offset by a decrease in revenue.

"ONTY recently announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono Inc., have temporarily suspended the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine). The suspension is the result of a suspected unexpected serious adverse reaction in a patient with multiple myeloma participating in an exploratory clinical trial. This decision was taken in alignment with the U.S. Food and Drug Administration's (FDA) clinical hold placed on the Investigational New Drug (IND) application for Stimuvax."

To read the entire report visit: http://www.investorsoup.com/lp/ONTY